Artificial Intelligence (AI) in Clinical Trials Market is Projected to Reach $4.8 billion by 2027- Exclusive Report by MarketsandMarkets™

Increasing Adoption of AI based Platform to Improve Productivity and Efficiency of Clinical Trials

Chicago, Oct. 18, 2022 (GLOBE NEWSWIRE) — According to the new market research report “Artificial Intelligence (AI) in Clinical Trials Market by Offering (Software, Services), Technology (Machine Learning, Deep Learning, Supervised), Application (Cardiovascular, Metabolic, Oncology), End User (Pharma, Biotech, CROs) – Global Forecasts to 2027″, is projected to reach USD 4.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 25.6% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42687548

Scope of the Artificial Intelligence (AI) in Clinical Trials Market Report:

The growth of this market is driven by the growing need to control development costs & reduce time involved in drug development, and Increasing adoption of AI based platform to improve productivity and efficiency of clinical trials, On the other hand, a lack of data sets in the field of clinical trials and the inadequate availability of skilled labor are some of the factors challenging the growth of the market

“Services segment is expected to grow at the highest rate during the forecast period”

Based on offering, the AI in clinical trials market is segmented into software and services. In 2021, the services segment accounted for the largest market share of the global AI in clinical trials services market and also expected to grow at the highest CAGR during the forecast period. The benefits associated with AI services and the strong demand for AI services among end users are the key factors driving the growth of this market segment.

“Machine learning technology segment accounted for the largest share of the global AI in clinical trials market”

Based on technology, the Artificial Intelligence (AI) in Clinical Trials Market is segmented into machine learning and other technologies. The machine learning segment accounted for the largest share of the global market in 2021 and expected to grow at the highest CAGR during the forecast period. The machine learning technology segment further segmented into deep learning, supervised learning, and other machine learning technologies. Deep learning segment accounted for the largest share of the market in 2021, and this segment also expected to grow at the highest CAGR during the forecast period.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=42687548

“The oncology application segment accounted for the largest share of the AI in clinical trials market in 2021”

On the basis of application, the Artificial Intelligence (AI) in Clinical Trials Market is segmented into neurological diseases and condition, cardiovascular diseases, metabolic diseases, infectious disease, immunology diseases, and other applications. The oncology segment accounted for the largest share of the market in 2021, owing to the increasing demand for effective cancer drugs and a large number of drug trials in the field of oncology is contributing to the adoption of AI-enabled technologies in this application area. Also, many players are developing and adopting oncology-based AI tools for clinical trials, thus impelling the segment growth. The infectious diseases segment is estimated to register the highest CAGR during the forecast period, owing to the increasing number of clinical trials for vaccine and drugs for covid-19 and other infectious disease and rising investment in R&D for infectious diseases.

“Pharmaceutical & biotechnology companies segment accounted for the largest share of the global AI in clinical trials market”

On the basis of end user, the Artificial Intelligence (AI) in Clinical Trials Market is segmented into pharmaceutical & biotechnology companies, CROs, and other end users. The pharmaceutical & biotechnology companies segment accounted for the largest market share of Artificial Intelligence in Clinical Trials Market, in 2021. Factors such as increasing adoption of AI enabled technologies to improve productivity and efficiency of clinical trials. Furthermore, growing cross industry collaborations and partnership for leverging the AI solution for R&D and the overall development process. Hence driving the growth among this end user segment.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=42687548

Geographical Growth Scenario:

North America accounted for the largest share of the global AI in clinical trials market in 2021 and also expected to grow at the highest CAGR during the forecast period. North America, which comprises the US, and Canada forms the largest market for AI in clinical trials. These countries have been early adopters of AI technology in clinical trials and development. Presence of key established players, well-established pharmaceutical and biotechnology industry, and high focus on R&D & substantial investment are some of the key factors responsible for the large share and high growth rate of this market

Key Players:

Prominent players in this Artificial Intelligence in Clinical Trials Market are IBM corporation, Exscientia, Saama Technologies, Unlearn.AI, Inc., BioSymetrics, Euretos, Trials.Ai, Insilico Medicine, Ardigen, Pharmaseal, Koninklijke Philips N.V., Intel, Numerate, AiCure, LLC., Envisagenics, NURITAs, BioAge Labs, Inc., Symphony AI., Median Technologies, Innoplexus, Antidote Technologies, Inc., GNS Healthcare, Koneksa Health, Halo Health Systems, and DEEP LENS AI. Players adopted organic as well as inorganic growth strategies such as product upgrades, collaborations, agreements, partnerships, and acquisitions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Browse Adjacent Markets@ Healthcare IT Market Research Reports & Consulting

CONTACT: About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com